Liver disease spectrum in hospitalized type 2 diabetes and related risk factors analysis of nonalcoholic fatty liver disease

National Medical Journal of China

Volumn 93, Issue 4, 2013, Pages 270-274

  Yan, Yan ^a   Bian, Hua ^a   Xia, Ming Feng ^a   Yan, Hong Mei ^a   Chang, Xin Xia ^a   Yao, Xiu Zhong ^b   Rao, Sheng Xiang ^b   Zeng, Meng Su ^b   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

^b NONE

Author keywords

Diabetes mellitus, type 2; Fatty liver, non alcoholic; Liver diseases

Indexed keywords

ALANINE AMINOTRANSFERASE; C PEPTIDE; LIVER ENZYME; URIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DIAGNOSTIC ACCURACY; DISEASE DURATION; ECHOGRAPHY; FEMALE; GOLD STANDARD; HUMAN; LABORATORY TEST; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; URIC ACID BLOOD LEVEL;

ADULT; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; INPATIENTS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84874339900     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2013.04.008     Document Type: Article

References (15)

1. Angulo P. Nonalcoholic fatty liver disease. Rev Gastroenterol Mex, 2005, 70 Suppl 3:52-56.
2. Siddiqi F, Carter L, Peltekian K M. Diabetes mellitis: risk factor for advanced liver disease. CMAJ, 2011, 183:586.
3. Harrison S A. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol, 2006, 40:68-76.
4. Farrell G C, Chitturi S, Lau G K, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol, 2007, 22:775-777.
5. 2008, 88: 531-533.
6. Browning J D, Szezepaniak L S, Dobbins R, et al. Prevalence of the hepatic steatosis in an urban population in the united states: impact of ethnicity. Hepatology, 2004, 40:1387-1395.
7. 2010:531-534.
8. 2005, 13:83-88.
9. Forlani G, Di Bonito P, Mannucci E, et al. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest, 2008, 31:146-152.
10. Morling J R, Strachan M W, Hayes P C, et al. Prevalence of abnormal plasma liver enzymes in older people with Type 2 diabetes. Diabet Med, 2012, 29:488-491.
11. Banderas D Z, Escobedo J, Gonzalez E, et al. γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol, 2012, 24:805-810.
12. Schindhelm R K, Diamant M, Dekker J M, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev, 2006, 22:437-443.
13. Pmti D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine armnotransferase levels. Ann Intern Med, 2002, 137:1-10.
14. Leite N C, Villela-nogueira C A. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int, 2011, 31:700-706.
15. Dongiovanni P, Fracanzani A L, Fargion S, et al. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol, 2011, 55:920-932.